# iRadimed Corporation (IRMD) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Health Care Technology. Price $83.45, market value $1.1 billion.

## Valuation
- **P/E (trailing): 46.6×** (5-yr avg 41.6×, 3-yr avg 41.8×). iRadimed Corporation trades at 46.6× trailing earnings, close to its own five-year average of 41.6×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 34.6×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 2.08**. A PEG of 2.08 means the P/E is high relative to expected earnings growth; the price already assumes a lot.
- **Price / sales: 12.4×**. Each dollar of revenue is priced at 12.4×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 10.5×**. The shares trade at 10.5× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 2.4%** (5-yr avg 2.0%). Free cash flow equals 2.4% of the market value, above its five-year average of 2.0%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 2.1%**. The inverse of the P/E: 2.1% of the price is earned each year.

## Profitability
- **Gross margin: 75.9%**. iRadimed Corporation keeps 75.9% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 31.9%**. 31.9% of revenue is left after running the business, an exceptional level.
- **Net margin: 26.8%**. 26.8% of each dollar of sales reaches the bottom line.
- **Return on equity: 23.8%**. 23.8% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on assets: 21.2%**. Each dollar of assets produces 21.2% of profit.

## Growth
- **Revenue growth (1 yr): 14.4%** (3-yr 16.3%/yr, 5-yr 21.5%/yr). Revenue grew 14.4% over the last year, against 21.5% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 16.7%** (3-yr 19.7%/yr, 5-yr 73.9%/yr). Earnings per share rose 16.7%, roughly in step with revenue.
- **Free-cash-flow growth (3 yr): 23.1%/yr**. Free cash flow has compounded at 23.1% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Current ratio: 7.98** (quick 7.98). Current assets cover the next year's liabilities 7.98 times.
- **Altman Z-score: 48.79**. A Z-score of 48.79 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend yield: 0.96%** ($0.77 per share, trailing). iRadimed Corporation yields 0.96%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 67%** (63% of free cash flow). 67% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 1**. 1 straight year of increases.

## Price and momentum
- **Total return (1 yr): 17.0%** (YTD -13.9%, 3-mo -10.3%). The shares are up 17.0% over twelve months including dividends.
- **From 52-week high: -22.7%** (23.0% above the low). Trading 23% below its 52-week high.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 29**. An RSI of 29 is oversold; bounces are common, but oversold can stay oversold in a real decline.
- **Beta (1 yr): 0.68** (volatility 32%). Beta of 0.68 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IRMD · Page: https://foliofundamentals.com/stocks/irmd

Not investment advice.